GEORGE F TIDMARSH
CIK 1287235 · President, CEO & Secretary · last filed 2025-02-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3
Companies
4
Total Filings
55
Lifetime Open-Market Net
$961.4K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| REVBW | Director | 268 | $0.01 | $3 | $389.1K | 12 | 2025-02-13 |
| Odonate Therapeutics, Inc. (ODT) Delisted | Director | 77,331 | $1.12 | $86.6K | $0 | 3 | 2019-09-23 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | President, CEO & Secretary | 1,285,895 | $6.22 | $8.00M | $552.2K | 35 | 2019-04-17 |
| SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted | CSO and Head of R&D Operations | 40,000 | $1.03 | $41.2K | $20.1K | 3 | 2011-01-03 |
Recent Filings · Page 2 of 6
55 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-02-10 | REVBW | Buy (P) | +31,000 | $79.1K | EDGAR |
| 2022-02-09 | REVBW | Buy (P) | +52,000 | $132.9K | EDGAR |
| 2022-02-08 | REVBW | Buy (P) | +50,000 | $128.0K | EDGAR |
| 2019-09-23 | Odonate Therapeutics, Inc. (ODT) Delisted | Exer (M) | +151,291 | $0 | EDGAR |
| 2019-04-17 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +2 | $12 | EDGAR |
| 2019-04-02 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +94 | $514 | EDGAR |
| 2019-03-19 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +195 | $1.3K | EDGAR |
| 2019-03-04 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +261 | $1.3K | EDGAR |
| 2019-02-19 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +239 | $1.3K | EDGAR |
| 2019-02-04 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +246 | $1.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.